Canagliflozin review – safety and efficacy profile in patients with T2DM

Canagliflozin is a sodium glucose-cotransporter (SGLT) receptor inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). This article reviews the mechanism of action of SGLT-2 receptor inhibitors and the efficacy of canagliflozin as an antidiabetic agent, its cardiovascular and renal...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakher, Haroon, Chang, Tara I, Tan, Marilyn, Mahaffey, Kenneth W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363491/
https://www.ncbi.nlm.nih.gov/pubmed/30787627
http://dx.doi.org/10.2147/DMSO.S184437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363491/
https://www.ncbi.nlm.nih.gov/pubmed/30787627
http://dx.doi.org/10.2147/DMSO.S184437

Ejemplares similares